MarketPulse
securities fraudclass action lawsuitshareholder rights

uniQure Securities Class Action Seeks Investors Over FDA Approval Claims

BenzingaBenzinga
|||1 min read
Key Takeaway

uniQure faces securities class action lawsuit over allegedly false FDA approval statements. Investors who purchased stock between September-October 2025 can join the case by April 2026.

uniQure Securities Class Action Seeks Investors Over FDA Approval Claims
$QUREnegative

The Schall Law Firm is organizing a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased the company's securities during a specific window in late 2025. The lawsuit alleges that the biopharmaceutical company made materially false and misleading statements regarding FDA approval prospects for its Pivotal Study and mischaracterized the risk of delays to its Biologics License Application (BLA) timeline.

According to the litigation notice, eligible investors are those who purchased uniQure securities between September 24, 2025, and October 31, 2025, and experienced financial losses as a result of the alleged misrepresentations. The class action mechanism allows multiple affected shareholders to consolidate their claims into a single proceeding against the company.

Investors seeking to participate in the lawsuit or be appointed as lead plaintiff must contact the Schall Law Firm before the April 13, 2026 deadline. The firm specializes in securities litigation and represents shareholders alleging violations of federal securities laws.

Topics

securities fraudclass action lawsuitshareholder rightsmisleading statementsFDA approvalBLA timeline

Source: Benzinga

Back to newsPublished Feb 20

Related Coverage

GlobeNewswire Inc.

FDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.

ARGX
GlobeNewswire Inc.

FSK Securities Fraud Lawsuit: Investors Sought for Class Action Over Misleading Statements

Schall Law Firm seeks $FSK investors for class action lawsuit alleging false statements on portfolio restructuring, valuations, and dividend strength between May 2024 and February 2026.

FSK
GlobeNewswire Inc.

Securities Fraud Investigations Target LKQ, Molina, MongoDB, and Power Solutions

Grabar Law Office investigates four companies for alleged securities fraud involving false statements about business performance, causing stock price inflation and investor losses.

MOHLKQMDB
GlobeNewswire Inc.

POET Technologies Hit with Securities Fraud Lawsuit Over PFIC Disclosure Failures

Kirby McInerney LLP files class action against POET Technologies for alleged securities fraud involving PFIC misrepresentation and confidentiality breaches, triggering steep stock declines.

POET
GlobeNewswire Inc.

LakeShore Biopharma Faces Securities Probe Over Alleged Misleading Statements

The Schall Law Firm investigates LakeShore Biopharma for alleged securities violations, including false statements and material information failures, recruiting affected shareholders.

LSBCF
GlobeNewswire Inc.

CCRN Under Investigation for Alleged Securities Violations

Schall Law Firm investigates Cross Country Healthcare ($CCRN) for alleged securities violations involving false statements or material disclosure failures to investors.

CCRN